Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Biogen Idec



) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.5%. By the end of trading, Biogen Idec fell $1.57 (-1%) to $152.83 on average volume. Throughout the day, 936,711 shares of Biogen Idec exchanged hands as compared to its average daily volume of 912,900 shares. The stock ranged in price between $152.64-$155.50 after having opened the day at $155 as compared to the previous trading day's close of $154.40. Other companies within the Health Care sector that declined today were:

Merrimack Pharmaceuticals



), down 16.9%,

MEI Pharma



), down 11.1%,

China Pharma



), down 9.5%, and




), down 8.6%.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $36.53 billion and is part of the


industry. The company has a P/E ratio of 28, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are up 40.5% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates Biogen Idec as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front,

Peregrine Pharmaceuticals


TheStreet Recommends


), up 46.6%,

Bovie Medical Corporation



), up 19.7%,

Graymark Healthcare



), up 17.8%, and

Echo Therapeutics



), up 15.8%, were all gainers within the health care sector with

Regeneron Pharmaceuticals



) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge!

Free download now